Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) radioligand therapy is an option that is increasingly being used for treatment of metastatic castration-resistant prostate cancer. This delivers β-radiation to cells expressing PSMA and high accumulation of the radiopharmaceutical occurs in the kidneys. Here we report three cases of radiation nephropathy with severe chronic kidney disease induced by renal thrombotic microangiopathy following extensive treatment with 177Lu-PSMA radioligand therapy.
European urology. 2022 Jun 07 [Epub]
Hannah Schäfer, Sarah Mayr, Maike Büttner-Herold, Karina Knorr, Lisa Steinhelfer, Carsten A Böger, Jürgen E Gschwend, Uwe Heemann, Matthias Eiber, Christoph Schmaderer, Robert Tauber
Department of Nephrology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany. Electronic address: ., Department of Nephrology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Department of Nephropathology, Institute of Pathology, Friedrich-Alexander University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany., Department of Nuclear Medicine, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Department of Nephrology, Diabetology and Rheumatology, Hospital Traunstein, Traunstein, Germany; KfH Kidney Center Traunstein, Traunstein, Germany; Department of Nephrology, University Hospital Regensburg, Regensburg, Germany., Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany. Electronic address: .